



Brussels, 18 November 2025
(OR. en)

15587/25

COMPET 1180
MI 919
IND 514
INTER-REP 116

NOTE

From:	General Secretariat of the Council
To:	Delegations
Subject:	Presentation by European Biosolutions Coalition (agenda item 2) at the Working Party on Competitiveness and Growth (High Level) on 18 November 2025


Delegations will find attached a presentation by European Biosolutions Coalition, with a view to the discussion by the Working Party on Competitiveness and Growth (High Level) at its meeting on 18 November 2025.

This document contains a presentation by an external stakeholder and the views expressed therein are solely those of the third party it originates from. This document cannot be regarded as stating an official position of the Council. It does not reflect the views of the Council or of its members.


European Biosolutions Coalition

COMPET High-Level Group Meeting
18 November 2025

Speaker: Sofie Carsten Nielsen, Director, European Biosolutions
Coalition - SCN@di.dk
Contact person in Brussels: Andreas Gram Drachmann, Senior
Advisor, European Biosolutions Coalition - ANGD@di.dk




Biosolutions are part of the bioeconomy, and we share a heritage with life science



Source: Illustration made by ADC.
Note: The sizes of the circles are illustrative and do not represent the actual market values.


What is the European Biosolutions Coalition?

- A Coalition of like-minded and ambitious national industry organizations
- **Purpose:** To highlight the importance of streamlining the regulatory framework for biosolutions in the EU and member states
- **Goal:** To have biosolutions included in the upcoming European Biotech Act I & II. Which means: Develop a framework for the fast approval of biosolutions



What we want: A Bold and Broad Biotech Act

1. Develop a framework for the fast approval of biosolutions
2. Develop and use a Risk-Benefit Approach
3. Invest in Research, Development, and Innovation
4. Improve incentives to invest in scaling and infrastructure capacity
5. Develop a European model of market access for biosolutions
6. Ensure Fair EU Classification and revise NACE codes




Company presentation on behalf of European Biosolutions Coalition

Koppert:

Speaker: Peter Maes, Director of Transformation – Pmaes@koppert.nl

Contact person: Ioannis Tzouros, Public Affairs Manager - ITzouros@koppert.nl





Koppert



Our core message:

- Biocontrol is a strategic asset for Europe's competitiveness, and food security, **but:**
- Outdated regulatory frameworks stifle EU innovation and competitiveness
- Inefficient regulations are in the way of building resilience and strategic autonomy in agriculture- biocontrol reduces dependency on chemicals.

Let's unlock the full potential of biocontrol—together.



Biocontrol as a pillar of the EU bioeconomy

Biocontrol agents (microorganisms, natural substances, semiochemicals, and beneficial insects) are essential to:

- a) Integrated Pest Management (IPM).
- b) Organic farming.
- c) Reducing chemical pesticide use and improving biodiversity.
- d) The European biocontrol market is valued at €1.6 billion, representing 10% of the crop protection market, and growing at 8–10% CAGR.



Biocontrol is essential for:

- a) Resilient food systems and agriculture.
- b) Farmer empowerment and growing the rural economy.
- c) Increasing European food security and resilience in food supply chain.

Despite its benefits, biocontrol faces systemic regulatory barriers.



Uneven Playing Field

The Problem:

- Regulation (EC) No 1107/2009 was created for chemical pesticides, not for **biocontrol solutions** that offer safer and more environmentally sustainable alternatives.
- **Approval timelines** average 8–10 years, compared to 2–3 years in the US or Brazil.
- **Unclear legal definitions** and inconsistent interpretation create uncertainty, discouraging investment and innovation.



Our message to the Council:

- a) The current framework does not promote innovation and investment.
- b) Lack of incentives: Farmers who adopt biocontrol face higher costs and limited product options, while SMEs driving innovation are held back by lengthy approvals and regulatory uncertainty.
- c) Agencies lack biocontrol-specific expertise.
- d) Duplication of work across Member States wastes resources.



Our message to the Council

What We Propose

- a) Fast-track authorisation for biocontrol products.
- b) Legal definition of biocontrol in EU law.
- c) One product, one evaluation.
- d) Dedicated Biocontrol Agency or unit within EFSA.
- e) Eventually, dedicated regulation on biocontrol